Compare GPI & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPI | ALKS |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.5B |
| IPO Year | 1997 | 2012 |
| Metric | GPI | ALKS |
|---|---|---|
| Price | $317.47 | $28.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $460.86 | $43.43 |
| AVG Volume (30 Days) | 143.3K | ★ 1.9M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 25.24 | 1.43 |
| Revenue | ★ $11,123,721,000.00 | $1,475,899,000.00 |
| Revenue This Year | $3.68 | $24.06 |
| Revenue Next Year | $3.19 | $4.53 |
| P/E Ratio | ★ $12.56 | $19.86 |
| Revenue Growth | ★ 2.17 | N/A |
| 52 Week Low | $292.44 | $25.17 |
| 52 Week High | $488.39 | $36.32 |
| Indicator | GPI | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 39.31 |
| Support Level | $306.96 | $27.48 |
| Resistance Level | $409.75 | $28.75 |
| Average True Range (ATR) | 10.91 | 0.91 |
| MACD | 1.95 | 0.01 |
| Stochastic Oscillator | 66.73 | 34.88 |
Group 1 owns and operates 32 collision centers and 254 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 109 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.